Gary Nachman Recent News
BMO Capital Markets: Lannett Making Progress With Pipeline, Cost Savings
BMO Smells Opportunity In OptiNose
Flexion Therapeutics Just Hit A Major Milestone
Valeant Expresses Confidence In Outlook, But Might Be Too Early To Get Bullish
Pershing Square's Valeant Sale Sends 'Untimely Poor Signal'
Analysts Having Difficulty Getting Comfortable With Valeant's Fundamentals
Mallinckrodt Nuclear Biz Sale A Positive In BMO's View, Maintains Outperform
Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines
Pacira Shares Tumble Following BMO's New Underperform Rating
4 Reasons To Own Horizon Pharma Shares
BMO Starts Valeant At Market Perform On Debt Burden, Execution Uncertainty
Goldman Downgrades Valeant, Sees 'Long Road' For Controversial Stock
Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory Panel
Leerink Swann Lowers Sucampo Pharmaceuticals (SCMP) Valuation To $6 - $7
Valeant Pharmaceuticals International’s (VRX) Fourth-Quarter Review